报价延迟最少15分钟:2025/11/22 20:11 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.57/-3.01
|
|
企业价值
119.26M
|
| 资产负债 |
|
每股账面净值
1.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
148.34M
|
|
每股收益
1.88
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. |
